The Clinical Efficacy of Immunomodulators in RA Patients
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study includes naive patients and csDMARDs-IR RA patients, treated with different
regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors
for 24 weeks. The disease activity and drug response will be observed. The immune disorder
and synovial function will be evaluated at the same time.